SNBIF.US SanBio Company Limited

Healthcare Biotechnology USA Stocks
16.45 USD
Close of Nov 17, 2026
16.45 16.45
Market cap
USD 1.28B
P/E
-
P/B
135.51x
ROE
-30.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jul 2026.

Is SNBIF.US undervalued?

Graham number

The Graham number of SanBio Company Limited cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

SanBio Company Limited fundamental analysis

No fundamental analysis for SanBio Company Limited yet.

SanBio Company Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About SanBio Company Limited

SanBio Company Limited engages in the development, production, and sale of regenerative cell medicines for the central nervous system in Japan and the United States. It develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury. The company's research pipeline products also comprise SB623 for chronic disease, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, Alzheimer's disease, etc.; SB618 to tre…

Full company profile